{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T21:00:25Z","timestamp":1784926825920,"version":"3.55.0"},"reference-count":67,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","funder":[{"name":"Swiss Cancer League","award":["KLS-6218-08-2024 BIL"],"award-info":[{"award-number":["KLS-6218-08-2024 BIL"]}]},{"name":"Swiss Cancer League","award":["KLS-6150-08-2024 BIL"],"award-info":[{"award-number":["KLS-6150-08-2024 BIL"]}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:p>\n                    KRAS driver mutations have classically been considered undruggable by direct inhibitors in non\u2013small cell lung cancer (NSCLC) as well as other solid tumors. However, recent advances have led to the first successful direct KRAS inhibitors, beginning with the development of KRAS\n                    <jats:sup>G12C<\/jats:sup>\n                    inhibitors targeting the inactive GDP-bound state of KRAS. These initial KRAS\n                    <jats:sup>G12C<\/jats:sup>\n                    (OFF) inhibitors demonstrated real but modest activity in KRAS\n                    <jats:sup>G12C<\/jats:sup>\n                    -mutated mNSCLC. The development of more potent optimized KRAS\n                    <jats:sup>G12C<\/jats:sup>\n                    (OFF) inhibitors has sought to improve upon the clinical activity of the initial raft of KRAS\n                    <jats:sup>G12C<\/jats:sup>\n                    (OFF) inhibitors. Combination therapy with PD-1 inhibitors, as well as other classes of drugs, is also under intense investigation in NSCLC and other solid tumors. Nevertheless, primary and acquired resistance, as well as a variable and peculiar tendency to autoimmune hepatitis, have complicated efforts to develop this class of inhibitors in KRAS\n                    <jats:sup>G12C<\/jats:sup>\n                    -mutated mNSCLC. In parallel, new direct inhibitor classes have emerged recently, including tri-complex ON-state inhibitors and dual-state ON\/OFF inhibitors capable of targeting not only KRAS\n                    <jats:sup>G12C<\/jats:sup>\n                    but also other KRAS mutations, as well as panKRAS and panRAS strategies. These agents have the potential to broaden the activity of initial KRAS\n                    <jats:sup>G12C<\/jats:sup>\n                    (OFF) inhibitors and to avoid certain mechanisms of resistance and toxicity, but remain early in development with limited data. The KRAS therapeutic landscape is evolving rapidly, with many promising competing strategies each seeking to distinguish itself in an increasingly crowded therapeutic landscape.\n                  <\/jats:p>","DOI":"10.1097\/ppo.0000000000000842","type":"journal-article","created":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T20:00:20Z","timestamp":1784923220000},"update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["KRAS-mutated Non\u2013Small Cell Lung Cancer"],"prefix":"10.1097","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9953-6865","authenticated-orcid":false,"given":"T\u00e4mer","family":"El Saadany","sequence":"first","affiliation":[{"name":"Division of Medical Oncology & Hematology, Princess Margaret Cancer Centre, University Health Network"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N\u00faria","family":"Aeschlimann","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology & Hematology, Princess Margaret Cancer Centre, University Health Network"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian","family":"Sacher","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology & Hematology, Princess Margaret Cancer Centre, University Health Network"},{"name":"Departments of Medicine & Immunology, University of Toronto, Toronto, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,7]]},"reference":[{"key":"R1-20260724","doi-asserted-by":"crossref","first-page":"3328","DOI":"10.1073\/pnas.78.6.3328","article-title":"Analysis of two divergent rat genomic clones homologous to the transforming gene of Harvey murine sarcoma virus","volume":"78","author":"DeFeo","year":"1981","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R2-20260724","first-page":"1339","article-title":"Mouse cells contain two distinct ras gene mRNA species that can be translated into a p21 onc protein","volume":"2","author":"Ellis","year":"1982","journal-title":"Mol Cell Biol"},{"key":"R3-20260724","doi-asserted-by":"crossref","first-page":"27891","DOI":"10.1038\/srep27891","article-title":"Effectors and potential targets selectively upregulated in human KRAS-mutant lung adenocarcinomas","volume":"6","author":"Li","year":"2016","journal-title":"Sci Rep"},{"key":"R4-20260724","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1158\/2159-8290.CD-20-0187","article-title":"EGFR blockade reverts resistance to KRASG12C inhibition in colorectal cancer","volume":"10","author":"Amodio","year":"2020","journal-title":"Cancer Discov"},{"key":"R5-20260724","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/s41586-019-1694-1","article-title":"The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity","volume":"575","author":"Canon","year":"2019","journal-title":"Nature"},{"key":"R6-20260724","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/313241a0","article-title":"Requirement for ras proto-oncogene function during serum-stimulated growth of NIH 3T3 cells","volume":"313","author":"Mulcahy","year":"1985","journal-title":"Nature"},{"key":"R7-20260724","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/j.cell.2012.01.058","article-title":"Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism","volume":"149","author":"Ying","year":"2012","journal-title":"Cell"},{"key":"R8-20260724","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1038\/385544a0","article-title":"Suppression of c-Myc-induced apoptosis by Ras signalling through PI(3)K and PKB","volume":"385","author":"Kauffmann-Zeh","year":"1997","journal-title":"Nature"},{"key":"R9-20260724","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1158\/1541-7786.MCR-15-0203","article-title":"Biochemical and structural analysis of common cancer-associated KRAS mutations","volume":"13","author":"Hunter","year":"2015","journal-title":"Mol Cancer Res"},{"key":"R10-20260724","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1016\/j.jtho.2019.01.020","article-title":"Characteristics and outcomes of patients with metastatic KRAS-mutant lung adenocarcinomas: the Lung Cancer Mutation Consortium Experience","volume":"14","author":"El Osta","year":"2019","journal-title":"J Thorac Oncol"},{"key":"R11-20260724","doi-asserted-by":"crossref","first-page":"6169","DOI":"10.1158\/1078-0432.CCR-11-3265","article-title":"Molecular epidemiology of EGFR and KRAS mutations in 3,026 lung adenocarcinomas: higher susceptibility of women to smoking-related KRAS-mutant cancers","volume":"18","author":"Dogan","year":"2012","journal-title":"Clin Cancer Res"},{"key":"R12-20260724","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1158\/2159-8290.CD-14-1236","article-title":"Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities","volume":"5","author":"Skoulidis","year":"2015","journal-title":"Cancer Discov"},{"key":"R13-20260724","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1158\/2159-8290.CD-18-0689","article-title":"Suppression of STING associated with LKB1 loss in KRAS-driven lung cancer","volume":"9","author":"Kitajima","year":"2019","journal-title":"Cancer Discov"},{"key":"R14-20260724","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1056\/NEJMoa2103695","article-title":"Sotorasib for lung cancers with KRAS p.G12C mutation","volume":"384","author":"Skoulidis","year":"2021","journal-title":"N Engl J Med"},{"key":"R15-20260724","doi-asserted-by":"crossref","first-page":"7554","DOI":"10.1038\/s41467-024-51828-2","article-title":"RAS-ON inhibition overcomes clinical resistance to KRAS G12C-OFF covalent blockade","volume":"15","author":"Nokin","year":"2024","journal-title":"Nat Commun"},{"key":"R16-20260724","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1001\/jama.2017.3438","article-title":"Selumetinib plus docetaxel compared with docetaxel alone and progression-free survival in patients with KRAS-mutant advanced non-small cell lung cancer: the SELECT-1 randomized clinical trial","volume":"317","author":"J\u00e4nne","year":"2017","journal-title":"JAMA"},{"key":"R17-20260724","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1038\/nature12796","article-title":"K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions","volume":"503","author":"Ostrem","year":"2013","journal-title":"Nature"},{"key":"R18-20260724","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1158\/2159-8290.CD-19-1167","article-title":"The KRAS(G12C) inhibitor MRTX849 provides insight toward therapeutic susceptibility of KRAS-mutant cancers in mouse models and patients","volume":"10","author":"Hallin","year":"2020","journal-title":"Cancer Discov"},{"key":"R19-20260724","doi-asserted-by":"crossref","first-page":"2382","DOI":"10.1056\/NEJMoa2105281","article-title":"Acquired resistance to KRAS(G12C) inhibition in cancer","volume":"384","author":"Awad","year":"2021","journal-title":"N Engl J Med"},{"key":"R20-20260724","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1056\/NEJMoa2303810","article-title":"Single-agent divarasib (GDC-6036) in solid tumors with a KRAS G12C mutation","volume":"389","author":"Sacher","year":"2023","journal-title":"N Engl J Med"},{"key":"R21-20260724","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/j.jtho.2023.03.015","article-title":"D-1553 (Garsorasib), a potent and selective inhibitor of KRAS(G12C) in patients with NSCLC: phase 1 study results","volume":"18","author":"Li","year":"2023","journal-title":"J Thorac Oncol"},{"issue":"15_suppl","key":"R22-20260724","doi-asserted-by":"crossref","first-page":"3511","DOI":"10.1200\/JCO.2020.38.15_suppl.3511","article-title":"CodeBreak 100: phase I study of AMG 510, a novel KRASG12C inhibitor, in patients (pts) with advanced solid tumors other than non-small cell lung cancer (NSCLC) and colorectal cancer (CRC)","volume":"38","author":"Hong","year":"2020","journal-title":"J Clin Oncol"},{"key":"R23-20260724","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1056\/NEJMoa2204619","article-title":"Adagrasib in non\u2013small-cell lung cancer harboring a KRASG12C mutation","volume":"387","author":"J\u00e4nne","year":"2022","journal-title":"N Engl J Med"},{"key":"R26-20260724","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/S0140-6736(23)00221-0","article-title":"Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRAS(G12C) mutation: a randomised, open-label, phase 3 trial","volume":"401","author":"de Langen","year":"2023","journal-title":"Lancet"},{"key":"R27-20260724","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/S0140-6736(25)00866-9","article-title":"Adagrasib versus docetaxel in KRASG12C-mutated non-small-cell lung cancer (KRYSTAL-12): a randomised, open-label, phase 3 trial","volume":"406","author":"Barlesi","year":"2025","journal-title":"Lancet"},{"key":"R28-20260724","first-page":"100213","article-title":"Severe immune checkpoint inhibitor hepatitis in KRAS G12C-mutant NSCLC potentially triggered by sotorasib: case report","volume":"2","author":"Begum","year":"2021","journal-title":"JTO Clin Res Rep"},{"key":"R29-20260724","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1016\/j.jtho.2023.05.013","article-title":"Brief Report: severe sotorasib-related hepatotoxicity and non-liver adverse events associated with sequential anti-programmed cell death (ligand)1 and sotorasib therapy in KRASG12C-mutant lung cancer","volume":"18","author":"Chour","year":"2023","journal-title":"J Thorac Oncol"},{"key":"R30-20260724","doi-asserted-by":"crossref","first-page":"6473","DOI":"10.3390\/curroncol30070476","article-title":"Canadian consensus recommendations on the management of KRAS G12C-Mutated NSCLC","volume":"30","author":"Cheema","year":"2023","journal-title":"Curr Oncol"},{"key":"R31-20260724","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1158\/2159-8290.CD-22-1420","article-title":"Comutations and KRASG12C Inhibitor efficacy in advanced NSCLC","volume":"13","author":"Negrao","year":"2023","journal-title":"Cancer Discov"},{"key":"R32-20260724","doi-asserted-by":"crossref","first-page":"3249","DOI":"10.1200\/JCO-25-00040","article-title":"Single-agent divarasib in patients with KRAS G12C\u2013positive non\u2013small cell lung cancer: long-term follow-up of a phase I study","volume":"43","author":"Sacher","year":"2025","journal-title":"J Clin Oncol"},{"key":"R33-20260724","doi-asserted-by":"crossref","first-page":"3834","DOI":"10.1038\/s41467-026-69943-7","article-title":"Pan-tumor activity of olomorasib, a next-generation KRAS G12C inhibitor in KRAS G12C-mutant advanced solid tumors: a first-in-human study","volume":"17","author":"Murciano-Goroff","year":"2026","journal-title":"Nat Commun"},{"key":"R34-20260724","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/S2213-2600(24)00110-3","article-title":"Garsorasib in patients with KRAS(G12C)-mutated non-small-cell lung cancer in China: an open-label, multicentre, single-arm, phase 2 trial","volume":"12","author":"Li","year":"2024","journal-title":"Lancet Respir Med"},{"key":"R35-20260724","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1038\/s41591-024-03401-z","article-title":"Glecirasib in KRASG12C-mutated nonsmall-cell lung cancer: a phase 2b trial","volume":"31","author":"Shi","year":"2025","journal-title":"Nat Med"},{"issue":"8_suppl","key":"R36-20260724","doi-asserted-by":"crossref","first-page":"CT030","DOI":"10.1158\/1538-7445.AM2023-CT030","article-title":"Abstract CT030: phase I study of IBI351 (GFH925) monotherapy in patients with advanced solid tumors: updated results of the phase I study","volume":"83","author":"Zhou","year":"2023","journal-title":"Cancer Res"},{"key":"R37-20260724","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1016\/j.jtho.2024.08.005","article-title":"Efficacy and safety of KRAS G12C inhibitor IBI351 monotherapy in patients with advanced NSCLC: results from a phase 2 pivotal study","volume":"19","author":"Zhou","year":"2024","journal-title":"J Thorac Oncol"},{"key":"R38-20260724","doi-asserted-by":"crossref","first-page":"106311","DOI":"10.1016\/j.esmoop.2026.106311","article-title":"4MO Updated results for MK-1084 + pembrolizumab in KRAS G12C-mutated (mut) metastatic non-small cell lung cancer (mNSCLC) enrolled in KANDLELIT-001","volume":"11","author":"Sacher","year":"2026","journal-title":"ESMO Open"},{"key":"R39-20260724","doi-asserted-by":"crossref","first-page":"CT020","DOI":"10.1158\/1538-7445.AM2026-CT020","article-title":"Safety and efficacy of Elisrasib (D3S-001), a next generation GDP-bound KRAS G12C inhibitor, as monotherapy in advanced non-small cell lung cancer (NSCLC) previously treated with or without a KRAS G12C inhibitor: results from a phase 1\/2 study","volume":"86","author":"Cho","year":"2026","journal-title":"Cancer Res"},{"issue":"12_suppl","key":"R40-20260724","doi-asserted-by":"crossref","first-page":"ND11","DOI":"10.1158\/1538-7445.AM2022-ND11","article-title":"Abstract ND11: Discovery of GDC-6036, a clinical stage treatment for KRAS G12C-positive cancers","volume":"82","author":"Purkey","year":"2022","journal-title":"Cancer Res"},{"issue":"36_suppl","key":"R41-20260724","doi-asserted-by":"crossref","first-page":"468214","DOI":"10.1200\/JCO.2024.42.36_suppl.468214","article-title":"A pivotal phase 2 single-arm study of glecirasib (JAB-21822) in patients with NSCLC harboring KRAS G12C mutation","volume":"42","author":"Shi","year":"2024","journal-title":"J Clin Oncol"},{"key":"R42-20260724","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1038\/s41586-023-06123-3","article-title":"Pan-KRAS inhibitor disables oncogenic signalling and tumour growth","volume":"619","author":"Kim","year":"2023","journal-title":"Nature"},{"key":"R43-20260724","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1200\/JCO.2026.44.2_suppl.380","article-title":"A phase I first in human, open-label, multicenter study of BI3706674, KRAS multi-inhibitor, monotherapy in patients with advanced solid tumors bearing KRAS WT amp","volume":"44","author":"Varkaris","year":"2026","journal-title":"J Clin Oncol"},{"key":"R44-20260724","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1158\/2159-8290.CD-21-0365","article-title":"Clinical acquired resistance to KRASG12C Inhibition through a novel KRAS Switch-II pocket mutation and polyclonal alterations converging on RAS\u2013MAPK reactivation","volume":"11","author":"Tanaka","year":"2021","journal-title":"Cancer Discov"},{"key":"R45-20260724","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1126\/science.adg9652","article-title":"Chemical remodeling of a cellular chaperone to target the active state of mutant KRAS","volume":"381","author":"Schulze","year":"2023","journal-title":"Science"},{"key":"R46-20260724","doi-asserted-by":"crossref","first-page":"6041","DOI":"10.1021\/acs.jmedchem.4c02313","article-title":"Discovery of elironrasib (RMC-6291), a potent and orally bioavailable, RAS(ON) G12C-selective, covalent tricomplex inhibitor for the treatment of patients with RAS G12C-addicted cancers","volume":"68","author":"Cregg","year":"2025","journal-title":"J Med Chem"},{"issue":"7_suppl","key":"R47-20260724","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1158\/1538-7445.AM2023-526","article-title":"Abstract 526: RMC-9805, a first-in-class, mutant-selective, covalent and oral KRASG12D(ON) inhibitor that induces apoptosis and drives tumor regression in preclinical models of KRASG12D cancers","volume":"83","author":"Jiang","year":"2023","journal-title":"Cancer Res"},{"key":"R48-20260724","doi-asserted-by":"crossref","first-page":"6064","DOI":"10.1021\/acs.jmedchem.4c02314","article-title":"Discovery of daraxonrasib (RMC-6236), a potent and orally bioavailable RAS(ON) multi-selective, noncovalent tri-complex Inhibitor for the treatment of patients with multiple RAS-addicted cancers","volume":"68","author":"Cregg","year":"2025","journal-title":"J Med Chem"},{"key":"R49-20260724","doi-asserted-by":"crossref","first-page":"S2112","DOI":"10.1016\/j.annonc.2025.10.689","article-title":"977MO Safety and efficacy of elironrasib, a RAS(ON) G12C-selective inhibitor, in previously treated patients with KRAS G12C NSCLC","volume":"36","author":"Tan","year":"2025","journal-title":"Ann Oncol"},{"key":"R50-20260724","doi-asserted-by":"crossref","first-page":"CT021","DOI":"10.1158\/1538-7445.AM2026-CT021","article-title":"CT021 - Preliminary safety and clinical activity of zoldonrasib (RMC-9805), an oral, RAS(ON) G12D-selective, tri-complex inhibitor in patients with previously treated KRAS G12D non-small cell lung cancer (NSCLC)","volume":"86","author":"Riess","year":"2026","journal-title":"Cancer Res"},{"issue":"8_suppl_2","key":"R51-20260724","doi-asserted-by":"crossref","first-page":"CT019","DOI":"10.1158\/1538-7445.AM2025-CT019","article-title":"Abstract CT019: Preliminary safety and antitumor activity of zoldonrasib (RMC-9805), an oral, RAS(ON) G12D-selective, tri-complex inhibitor in patients with KRAS G12D non-small cell lung cancer (NSCLC) from a phase 1 study in advanced solid tumors","volume":"85","author":"Arbour","year":"2025","journal-title":"Cancer Res"},{"key":"R52-20260724","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1016\/S1556-0864(25)00201-1","article-title":"6MO: Safety and clinical activity of daraxonrasib (RMC-6236) in RAS mutant non-small cell lung cancer (NSCLC)","volume":"20","author":"Punekar","year":"2025","journal-title":"J Thorac Oncol"},{"issue":"7_suppl","key":"R53-20260724","doi-asserted-by":"crossref","first-page":"LB163","DOI":"10.1158\/1538-7445.AM2024-LB163","article-title":"Abstract LB163: Discovery and characterization of QTX3544, a potent, selective, and orally bioavailable allosteric G12V preferring multi KRAS inhibitor","volume":"84","author":"Zhang","year":"2024","journal-title":"Cancer Res"},{"issue":"10_suppl","key":"R54-20260724","doi-asserted-by":"crossref","first-page":"B119","DOI":"10.1158\/1535-7163.TARG-25-B119","article-title":"Abstract B119: FMC-376, a dual inhibitor of ON + OFF states of KRAS G12C, is active in sotorasib resistant PDX models","volume":"24","author":"Wang","year":"2025","journal-title":"Mol Cancer Ther"},{"key":"R55-20260724","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1158\/2159-8290.CD-24-0840","article-title":"Discovery of BBO-8520, a first-in-class direct and covalent dual inhibitor of GTP-bound (ON) and GDP-bound (OFF) KRASG12C","volume":"15","author":"Maciag","year":"2025","journal-title":"Cancer Discov"},{"key":"R57-20260724","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1158\/2159-8290.CD-25-1280","article-title":"Discovery of BBO-11818, a potent and selective noncovalent inhibitor of (ON) and (OFF) KRAS with activity against multiple oncogenic mutants","volume":"16","author":"Stahlhut","year":"2026","journal-title":"Cancer Discov"},{"key":"R58-20260724","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/s42004-025-01662-4","article-title":"Discovery of KRAS(G12D) selective degrader ASP3082","volume":"8","author":"Yoshinari","year":"2025","journal-title":"Commun Chem"},{"key":"R59-20260724","doi-asserted-by":"crossref","first-page":"10238","DOI":"10.1021\/acs.jmedchem.5c00428","article-title":"Discovery and characterization of RP03707: a highly potent and selective KRASG12D PROTAC","volume":"68","author":"Ji","year":"2025","journal-title":"J Med Chem"},{"key":"R60-20260724","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1056\/NEJMoa2600752","article-title":"Setidegrasib in advanced non-small-cell lung cancer and pancreatic cancer","volume":"394","author":"Park","year":"2026","journal-title":"N Engl J Med"},{"key":"R61-20260724","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1158\/2767-9764.CRC-25-0001","article-title":"Glecirasib, a potent and selective covalent KRAS G12C inhibitor exhibiting synergism with cetuximab or SHP2 inhibitor JAB-3312","volume":"5","author":"Wang","year":"2025","journal-title":"Cancer Res Commun"},{"key":"R62-20260724","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1158\/1535-7163.MCT-24-0049","article-title":"Discovery of RGT-018: a potent, selective, and orally bioavailable SOS1 inhibitor for KRAS-driven cancers","volume":"23","author":"Xiao","year":"2024","journal-title":"Mol Cancer Ther"},{"key":"R63-20260724","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1158\/1078-0432.CCR-18-0368","article-title":"KRAS G12C NSCLC models are sensitive to direct targeting of KRAS in combination with PI3K inhibition","volume":"25","author":"Misale","year":"2019","journal-title":"Clin Cancer Res"},{"key":"R64-20260724","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/S1470-2045(25)00764-8","article-title":"Fulzerasib plus cetuximab in first-line KRASG12C-mutated non-small-cell lung cancer (KROCUS): a single-arm, multicentre, phase 1b\/2 trial","volume":"27","author":"Gregorc","year":"2026","journal-title":"Lancet Oncol"},{"key":"R65-20260724","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1016\/j.jtho.2022.07.025","article-title":"OA03.06 CodeBreaK 100\/101: first report of safety\/efficacy of sotorasib in combination with pembrolizumab or atezolizumab in advanced KRAS p.G12C NSCLC","volume":"17","author":"Li","year":"2022","journal-title":"J Thorac Oncol"},{"issue":"16_suppl","key":"R66-20260724","doi-asserted-by":"crossref","first-page":"8500","DOI":"10.1200\/JCO.2025.43.16_suppl.8500","article-title":"First-line adagrasib (ADA) with pembrolizumab (PEMBRO) in patients (pts) with advanced\/metastatic KRASG12C-mutated non-small cell lung cancer (NSCLC) from the phase 2 portion of the KRYSTAL-7 study","volume":"43","author":"J\u00e4nne","year":"2025","journal-title":"J Clin Oncol"},{"issue":"3, suppl 1","key":"R67-20260724","doi-asserted-by":"crossref","first-page":"S8","DOI":"10.1016\/S1556-0864(25)00200-X","article-title":"5MO: first-line adagrasib (ADA) with pembrolizumab (PEMBRO) in patients (pts) with advanced\/metastatic KRASG12C-mutated non-small cell lung cancer (NSCLC) and PD-L1 \u226550% from the phase II portion of KRYSTAL-7","volume":"20","author":"Garassino","year":"2025","journal-title":"J Thorac Oncol"},{"key":"R68-20260724","doi-asserted-by":"crossref","first-page":"S872","DOI":"10.1016\/j.annonc.2024.08.1449","article-title":"1394TiP KRYSTAL-7: a phase III study of first-line adagrasib plus pembrolizumab versus pembrolizumab alone in patients with advanced NSCLC with KRASG12C mutation","volume":"35","author":"Garassino","year":"2024","journal-title":"Ann Oncol"},{"key":"R69-20260724","doi-asserted-by":"crossref","first-page":"S42","DOI":"10.1016\/j.jtho.2024.09.075","article-title":"OA14.06 divarasib single-agent long-term follow-up and atezolizumab combination treatment in patients with KRAS G12C-positive NSCLC","volume":"19","author":"Sacher","year":"2024","journal-title":"J Thorac Oncol"},{"key":"R70-20260724","doi-asserted-by":"crossref","first-page":"103528","DOI":"10.1016\/j.jtho.2025.11.018","article-title":"Efficacy and safety of olomorasib in combination with pembrolizumab in treatment of patients with KRAS G12C-mutant advanced NSCLC","volume":"21","author":"Burns","year":"2026","journal-title":"J Thorac Oncol"}],"container-title":["The Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/PPO.0000000000000842","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T20:00:30Z","timestamp":1784923230000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/PPO.0000000000000842"}},"subtitle":["Drugging the Undruggable"],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":67,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/ppo.0000000000000842","relation":{},"ISSN":["1540-336X"],"issn-type":[{"value":"1540-336X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"2026-05-27","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2027-05-27","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}